Cargando…
Efficacy Endpoints in Clinical Trials in Actinic Keratosis
INTRODUCTION: Actinic keratosis is regarded as a chronic disease of the skin and, although fluctuating, is chronically progressive. Approval of new products for the treatment of actinic keratosis requires the use of a standard methodology in clinical trials which emphasize complete clearance of all...
Autores principales: | Skov, Torsten, Stockfleth, Eggert, Szeimies, Rolf-Markus, Berman, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109027/ https://www.ncbi.nlm.nih.gov/pubmed/29916197 http://dx.doi.org/10.1007/s13555-018-0247-0 |
Ejemplares similares
-
Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action
por: Schlesinger, Todd, et al.
Publicado: (2022) -
Use of Lesion Response Rate in Actinic Keratosis Trials
por: Szeimies, Rolf-Markus, et al.
Publicado: (2016) -
Evaluating the Efficacy and Safety of 4% 5-Fluorouracil Cream in Patients with Actinic Keratosis: An Expert Opinion
por: STOCKFLETH, Eggert, et al.
Publicado: (2023) -
Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project
por: MORTON, Colin, et al.
Publicado: (2023) -
The Overall Number of Actinic Keratosis Lesions Is Not Predictable by the Number of Visible Lesions: Consequences for Field-Directed Therapies
por: Stockfleth, Eggert, et al.
Publicado: (2021)